Targeted cancer therapy: what if the driver is just a messenger?
about
Rocaglamide, silvestrol and structurally related bioactive compounds from Aglaia speciesTwo hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.Proviral insertion in murine lymphomas 2 (PIM2) oncogene phosphorylates pyruvate kinase M2 (PKM2) and promotes glycolysis in cancer cellsThe PIM family of serine/threonine kinases in cancer.Combination of Pim kinase inhibitor SGI-1776 and bendamustine in B-cell lymphoma.The effects of phenoxodiol on the cell cycle of prostate cancer cell lines
P2860
Targeted cancer therapy: what if the driver is just a messenger?
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Targeted cancer therapy: what if the driver is just a messenger?
@en
type
label
Targeted cancer therapy: what if the driver is just a messenger?
@en
prefLabel
Targeted cancer therapy: what if the driver is just a messenger?
@en
P2860
P356
P1433
P1476
Targeted cancer therapy: what if the driver is just a messenger?
@en
P2093
Hans-Guido Wendel
Jonathan H Schatz
P2860
P304
P356
10.4161/CC.10.22.18288
P577
2011-11-15T00:00:00Z